Meeting
2020 ASCO Virtual Scientific Program
Therapeutic vulnerabilities among KRAS G12C mutant (mut) advanced cancers based on co-alteration (co-alt) patterns.
Authors
Maliha Nusrat
Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY
Maliha Nusrat , Jason Roszik , Vijaykumar Holla , Tiantian Cai , Meiyue Hong , Oluwadara Coker , Benny Johnson , Jordi Rodon Ahnert , Filip Janku , Scott Kopetz , Kenna Rael Shaw , Funda Meric-Bernstam , David S. Hong
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Tissue-Based Biomarkers
Citation
J Clin Oncol 38: 2020 (suppl; abstr 3625)
DOI
10.1200/JCO.2020.38.15_suppl.3625
Abstract #
3625
Poster Bd #
355
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Genomic classification of clinically advanced pancreatic ductal adenocarcinoma (PDAC) based on methylthioadenosine phosphorylase (MTAP) genomic loss (MTAP loss).
First Author: Natalie Ngoi
Poster
2020 ASCO Virtual Scientific Program
The landscape of MAP3K1/MAP2K4 alterations in gastrointestinal (GI) malignancies.
First Author: Matthew K Stein
Poster
2020 Gastrointestinal Cancers Symposium
Molecular profiling of early-stage colorectal cancer (CRC) using targeted next generation sequencing (NGS) to predict signatures of recurrence.
First Author: Michael C. Burns
Poster
2018 ASCO Annual Meeting
Seventeen percent of NGS 50 gene panel variants are not expressed in RNAseq.
First Author: Razelle Kurzrock